Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading 7.3% Higher

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPHGet Rating) (TSE:AUP) rose 7.3% during mid-day trading on Friday . The company traded as high as $8.58 and last traded at $8.51. Approximately 81,379 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 5,904,376 shares. The stock had previously closed at $7.93.

Analyst Ratings Changes

AUPH has been the subject of several recent research reports. Royal Bank of Canada upped their target price on Aurinia Pharmaceuticals from $10.00 to $11.00 and gave the company an “outperform” rating in a report on Tuesday, January 3rd. SVB Leerink cut their target price on Aurinia Pharmaceuticals from $17.00 to $12.00 and set an “outperform” rating on the stock in a research note on Friday, November 4th. Oppenheimer lowered shares of Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday, November 4th. StockNews.com started coverage on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 12th. They issued a “hold” rating on the stock. Finally, HC Wainwright reduced their target price on shares of Aurinia Pharmaceuticals from $26.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, November 7th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.50.

Aurinia Pharmaceuticals Price Performance

The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -10.04 and a beta of 0.87. The firm’s fifty day moving average is $5.60 and its two-hundred day moving average is $7.19.

Aurinia Pharmaceuticals (NASDAQ:AUPHGet Rating) (TSE:AUP) last posted its quarterly earnings data on Thursday, November 3rd. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.12. Aurinia Pharmaceuticals had a negative net margin of 89.50% and a negative return on equity of 26.03%. The business had revenue of $55.78 million during the quarter, compared to analysts’ expectations of $38.11 million. On average, equities analysts forecast that Aurinia Pharmaceuticals Inc. will post -0.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Douglas Lane & Associates LLC bought a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter worth approximately $53,000. Capital Investment Advisors LLC increased its holdings in shares of Aurinia Pharmaceuticals by 32.9% in the fourth quarter. Capital Investment Advisors LLC now owns 40,365 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 10,000 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Aurinia Pharmaceuticals by 9.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 407,351 shares of the biotechnology company’s stock valued at $3,063,000 after acquiring an additional 35,854 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of Aurinia Pharmaceuticals by 3.5% during the 3rd quarter. California State Teachers Retirement System now owns 156,647 shares of the biotechnology company’s stock worth $1,178,000 after acquiring an additional 5,306 shares in the last quarter. Finally, BNP Paribas Arbitrage SNC grew its holdings in shares of Aurinia Pharmaceuticals by 112.4% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 64,401 shares of the biotechnology company’s stock worth $484,000 after acquiring an additional 34,078 shares during the last quarter. 40.36% of the stock is currently owned by institutional investors.

About Aurinia Pharmaceuticals

(Get Rating)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.

Further Reading

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.